CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention

Thrombosis Research

Volumn 129, Issue 4, 2012, Pages 441-446

  Kassimis, George ^a   Davlouros, Periklis ^a   Xanthopoulou, Ioanna ^a   Stavrou, Eleana F ^b   Athanassiadou, Aglaia ^b   Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Clopidogrel; CYP2B65; CYP2C19; P2RY12; Percutaneous coronary intervention; Platelet reactivity

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYTOKINE; DRUG DERIVATIVE; TICLOPIDINE;

ADULT; ARTICLE; BLOOD SAMPLING; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; BLOOD; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; GREECE; PREVALENCE; STATISTICS; STENT; THROMBOSIS; TREATMENT OUTCOME;

COMORBIDITY; CORONARY ARTERY DISEASE; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREECE; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PREVALENCE; STENTS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84858340502     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.07.022     Document Type: Article

References (43)

1. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol. 49 2007 1505 1516
2. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation. 107 2003 2908 2913
3. T. Geisler, C. Zurn, R. Simonenko, M. Rapin, H. Kraibooj, and A. Kilias Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions Eur Heart J. 31 2010 59 66
4. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, and A. Schomig Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol. 53 2009 849 856
5. N.J. Breet, J.W. van Werkum, H.J. Bouman, J.C. Kelder, H.J. Ruven, and E.T. Bal Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA. 303 2010 754 762
6. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet. 376 2010 1312 1319
7. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med. 360 2009 354 362
8. G. Rudez, H.J. Bouman, J.W. van Werkum, F.W. Leebeek, A. Kruit, and H.J. Ruven Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions Circ Cardiovasc Genet. 2 2009 515 521
9. D. Taubert, N. von Beckerath, G. Grimberg, A. Lazar, N. Jung, and T. Goeser Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther. 80 2006 486 501
10. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Meneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med. 360 2009 363 375
11. D. Alexopoulos, G. Dimitropoulos, P. Davlouros, I. Xanthopoulou, G. Kassimis, and E.F. Stavrou Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel The Importance of CYP2C19*2 Genotyping JACC Cardiovasc Interv. 4 2011 403 410
12. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2 C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood. 108 2006 2244 2247
13. C. Varenhorst, S. James, D. Erlinge, J.T. Brandt, O.O. Braun, and M. Man Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J. 30 2009 1744 1752
14. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, and C.S. Ernest 2nd Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost. 5 2007 2429 2436
15. A. Harmsze, J.W. van Werkum, H.J. Bouman, H.J. Ruven, N.J. Breet, and J.M. Ten Berg Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation Pharmacogenet Genomics. 20 2010 18 25
16. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2 C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol. 51 2008 1925 1934
17. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, and K. Dorrler Cytochrome P450 2 C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J. 30 2009 916 922
18. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA. 304 2010 1821 1830
19. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain Cytochrome P450 2 C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet. 373 2009 309 317
20. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2 C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA. 302 2009 849 857
21. T. Geisler, E. Schaeffeler, J. Dippon, S. Winter, V. Buse, and C. Bischofs CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation Pharmacogenomics. 9 2008 1251 1259
22. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, and J. Stegherr Cytochrome 2 C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation. 121 2010 512 518
23. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet. 376 2010 1320 1328
24. H.J. Bouman, E. Schomig, J.W. van Werkum, J. Velder, C.M. Hackeng, and C. Hirschhauser Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med. 17 2011 110 116
25. D. Trenk, W. Hochholzer, M.F. Fromm, O. Zolk, C.M. Valina, and C. Stratz Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement Circ Cardiovasc Genet 2011
26. S.L. Hetherington, R.K. Singh, D. Lodwick, J.R. Thompson, A.H. Goodall, and N.J. Samani Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP Arterioscler Thromb Vasc Biol. 25 2005 252 257
27. E.I. Lev, R.T. Patel, S. Guthikonda, D. Lopez, P.F. Bray, and N.S. Kleiman Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel Thromb Res. 119 2007 355 360
28. D. Sibbing, O. von Beckerath, A. Schomig, A. Kastrati, and N. von Beckerath P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel J Thromb Haemost. 4 2006 912 914
29. J.W. van Werkum, A.M. Harmsze, E.H. Elsenberg, H.J. Bouman, J.M. ten Berg, and C.M. Hackeng The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence Platelets. 19 2008 479 488
30. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J. 29 2008 992 1000
31. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol. 56 2010 919 933
32. H.J. Bouman, A.M. Harmsze, J.W. van Werkum, N.J. Breet, T.O. Bergmeijer, and H. Ten Cate Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting Heart. 2011
33. W. Hochholzer, D. Trenk, M.F. Fromm, C.M. Valina, C. Stratz, and H.P. Bestehorn Impact of cytochrome P450 2 C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol. 55 2010 2427 2434
34. G. Pare, S.R. Mehta, S. Yusuf, S.S. Anand, S.J. Connolly, and J. Hirsh Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med. 363 2010 1704 1714
35. A.M. Harmsze, J.W. van Werkum, J.M. Ten Berg, B. Zwart, H.J. Bouman, and N.J. Breet CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study Eur Heart J. 31 2010 3046 3053
36. K.A. Tiroch, D. Sibbing, W. Koch, T. Roosen-Runge, J. Mehilli, and A. Schomig Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events Am Heart J. 160 2010 506 512
37. P.A. Gurbel, A.R. Shuldiner, K.P. Bliden, K. Ryan, R.E. Pakyz, and U.S. Tantry The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J. 161 2011 598 604
38. Y.H. Jeong, I.S. Kim, Y. Park, M.K. Kang, J.S. Koh, and S.J. Hwang Carriage of cytochrome 2 C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study JACC Cardiovasc Interv. 3 2010 731 741
39. E. Schaeffeler, M. Eichelbaum, U. Brinkmann, A. Penger, S. Asante-Poku, and U.M. Zanger Frequency of C3435T polymorphism of MDR1 gene in African people Lancet. 358 2001 383 384
40. G.D. Leschziner, T. Andrew, M. Pirmohamed, and M.R. Johnson ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research Pharmacogenomics J. 7 2007 154 179
41. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, U. Cavallari, and E. Trabetti Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease Thromb Res. 116 2005 491 497
42. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Cytochrome P450 2 C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12 G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics. 17 2007 1057 1064
43. S.J. Lee, I.S. Jung, E.J. Jung, J.Y. Choi, C.W. Yeo, and D.Y. Cho Identification of P2Y12 single-nucleotide polymorphisms and their influences on the variation in ADP-induced platelet aggregation Thromb Res. 127 2011 220 227